A Multicenter, Open-label Phase I/II Trial to Evaluate the Safety and Activity of CPC-P501 Protein Formulated With the Adjuvant AS15 as First-line Treatment in Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA.
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs P501 AS15 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 14 Dec 2007 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 09 Nov 2006 Status change